Anticoagulant drugs: VKA high dose vs vitamin K antagonist (VKA)
Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in any thromboembolic event compared with standard‐dose VKA (low certainty).
1 finding from 1 review
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people… 2020 · Cochrane Headline outcomes onlyRR 2.22 [0.79, 6.23]2 studies · 223 participantsLow